Illumina, Myriad Genetics provide U.S. access to HRD research test

By The Science Advisory Board staff writers

March 6, 2023 -- Illumina and Myriad Genetics have expanded a strategic partnership aimed at broadening access to oncology homologous recombination deficiency (HRD) testing for oncology.

Under the agreement, Illumina TruSight Oncology 500 HRD (TSO 500 HRD), a research-use-only test, is now available in the U.S.

The expanded partnership also establishes a companion diagnostic (CDx) testing alliance for the pharmaceutical industry, which will enable more clinical research for gene-based, targeted therapies, the firms said.

They noted that the agreement aligns Myriad's MyChoice CDx HRD technology with Illumina's pan-cancer test, TSO 500 HRD research test. Illumina developed the test with Merck and Myriad Genetics.

TSO 500 HRD is a single, comprehensive pan-cancer test designed to identify key genetic variants and homologous recombination deficiency critical for understanding cancer development and progression. HRD status is an important biomarker in tumors that harbor high levels of DNA damage, such as those present in ovarian, breast, prostate, and pancreatic cancers.

Myriad and Illumina's initial partnership led to Illumina's combined HRD and TSO 500 offering launch worldwide -- excluding the U.S. and Japan -- in June 2022.

After Illumina presentation highlighting Grail potential comes a possible EU fine
Illumina may be fined 10% of its annual revenues for completing the takeover of Grail in 2021 without European Union antitrust approval.
Illumina releases DRAGEN v4.0 secondary analysis platform
Illumina has released Illumina Dynamic Read Analysis for Genomics (DRAGEN) v4.0 as its most accurate and comprehensive secondary analysis platform. The...
Mouse DNA methylation array seeks to accelerate high-sample-throughput studies
Scientists have developed a mouse DNA methylation array that contains more than 296,000 probes and a murine methylome atlas of 1,239 diverse cell types,...
Illumina, Merck develop new oncology assay
Illumina codeveloped a research test with Merck that assesses a new genomic signature with its TruSight Oncology 500 assay.
Myriad Genetics sells Myriad RBM to Q2 Solutions
Myriad Genetics is selling its Myriad RBM contract research services business to Q2 Solutions, a wholly owned subsidiary of Iqvia, for an undisclosed...

Copyright © 2023

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter